Novel Oligonucleotide Therapeutics and Their Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".
Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 3805
Special Issue Editors
Interests: drug design; development and delivery; epigenetics; DNA methylation; LC-MS/MS
Interests: melatonin; glaucoma; eye care solutions; dry eye; contact lenses
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
New oligonucleotide therapeutics are becoming increasingly important. Recent approval of parenteral nanoparticle oligonucleotide formulations such as the Pfizer and Moderna COVID RNA vaccines, siRNA therapies such as, givosiran, patisiran, and aptamer therapies like pegaptanib highlight the importance and the increasing success of oligonucleotide delivery. While the promise of antisense oligonucleotide therapies have been anticipated since the late 90s, new oligonucleotide therapies are being produced, including those that induce exon skipping, novel aptamers, and the potential for delivery of gRNA for CRISPR gene editing. All of these promising oligonucleotide technologies converge on an important requirement: effective drug delivery methods that can get the oligonucleotide drugs into cells and target the drug to the right tissues. Nanoparticle delivery technology has advanced to meet some of these challenges and newer technologies are being developed that have extended half-lives, and target nanoparticles to particular tissues using “smart” materials, and chemical conjugation. This Special Issue covers the latest information on novel oligonucleotide therapeutics and their delivery. We are seeking original contributions and review articles in these areas.
Dr. Ted Lakowski
Dr. Alejandro Martínez-Åguila
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoparticle drug delivery
- siRNA
- aptamer
- anti-sense oligonucleotides
- bioconjugation
- miRNA
- Smart materials
- CRISPR
- therapeutic gene editing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.